Zenith Capital Corp

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694 which is in Phase 2b clinical trials for the treatment of metastatic castration resistant prostate cancer and metastatic triple negative breast cancer. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. The company was incorporated in 2013 and is headquartered in Calgary, Canada. Show More...